Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase

Retrovirology

Volumn 5, Issue , 2008, Pages

  Huigen, Marleen C D G ^a   van Ham, Petronella M ^a   de Graaf, Loek ^a   Kagan, Ron M ^b   Boucher, Charles A B ^a   Nijhuis, Monique ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CODON; COMBINATION CHEMOTHERAPY; DRUG TREATMENT FAILURE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MONOTHERAPY; NONHUMAN; PHENOTYPIC VARIATION; SITE DIRECTED MUTAGENESIS; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE; AMINO ACID SEQUENCE; CELL LINE; CYTOPATHOGENIC EFFECT; DIRECTED MOLECULAR EVOLUTION; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; IC 50; METABOLISM; MISSENSE MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; DIRECTED MOLECULAR EVOLUTION; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION; ZIDOVUDINE;

EID: 41549097303     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-5-20     Document Type: Article

References (46)

1. Yarchoan R Broder S Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report N Engl J Med 1987, 316:557-564 3543683
2. Larder BA Darby G Richman DD HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy Science 1989, 243:1731-1734 10.1126/science.2467383 2467383
3. Larder BA Coates KE Kemp SD Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture J Virol 1991, 65:5232-5236 249001 1716689
4. Harrigan PR Kinghorn I Bloor S Kemp SD Najera I Kohli A Larder BA Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility J Virol 1996, 70:5930-5934 190612 8709214
5. Kellam P Boucher CA Larder BA Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine Proc Natl Acad Sci U S A 1992, 89:1934-1938 48568 1371886 10.1073/pnas.89.5.1934
6. Kellam P Boucher CA Tijnagel JM Larder BA Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance J Gen Virol 1994, 75(Pt 2):341-351 7509370
7. Hooker DJ Tachedjian G Solomon AE Gurusinghe AD Land S Birch C Anderson JL Roy BM Arnold E Deacon NJ An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine J Virol 1996, 70:8010-8018 190874 8892925
8. Hanna GJ Johnson VA Kuritzkes DR Richman DD Brown AJ Savara AV Hazelwood JD D'Aquila RT Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine J Infect Dis 2000, 181:904-911 10.1086/315329 10720511
9. Marcelin AG Delaugerre C Wirden M Viegas P Simon A Katlama C Calvez V Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure J Med Virol 2004, 72:162-165 10.1002/jmv.10550 14635026
10. Yahi N Tamalet C Tourres C Tivoli N Ariasi F Volot F Gastaut JA Gallais H Moreau J Fantini J Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences J Clin Microbiol 1999, 37:4099-4106 85889 10565938
11. Boyer PL Sarafianos SG Arnold E Hughes SH Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase J Virol 2001, 75:4832-4842 114238 11312355 10.1128/JVI.75.10.4832-4842.2001
12. Selmi B Deval J Boretto J Canard B Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues Antivir Ther 2003, 8:143-154 12741627
13. Cane PA Green H Fearnhill E Dunn D Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase AIDS 2007, 21:447-455 10.1097/QAD.0b013e3280129964 17301563
14. Ceccherini-Silberstein F Gago F Santoro M Gori C Svicher V Rodriguez-Barrios F D'Arrigo R Ciccozzi M Bertoli A Monforte A Balzarini J Antinori A Perno CF High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations J Virol 2005, 79:10718-10729 1182657 16051864 10.1128/JVI.79.16.10718-10729.2005
15. Gonzales MJ Wu TD Taylor J Belitskaya I Kantor R Israelski D Chou S Zolopa AR Fessel WJ Shafer RW Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors AIDS 2003, 17:791-799 10.1097/00002030-200304110-00003 12660525
16. Perno CF Svicher V Ceccherini-Silberstein F Novel drug resistance mutations in HIV: Recognition and clinical relevance AIDS Rev 2006, 8:179-190 17219733
17. Rabinowitz M Myers L Banjevic M Chan A Sweetkind-Singer J Haberer J McCann K Wolkowicz R Accurate prediction of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization Bioinformatics 2006, 22:541-549 10.1093/bioinformatics/btk011 16368772
18. Rhee SY Fessel WJ Zolopa AR Hurley L Liu T Taylor J Nguyen DP Slome S Klein D Horberg M Flamm J Follansbee S Schapiro JM Shafer RW HIV-1 Protease and Reverse-Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance J Infect Dis 2005, 192:456-465 10.1086/ 431601 15995959
19. Saracino A Monno L Scudeller L Cibelli DC Tartaglia A Punzi G Torti C Lo CS Mazzotta F Scotto G Carosi G Angarano G Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors J Med Virol 2006, 78(1):9-17 10.1002/ jmv.20500 16299731
20. Svicher V Sing T Santoro MM Forbici F Rodriguez-Barrios F Bertoli A Beerenwinkel N Bellocchi MC Gago F d'Arminio MA Antinori A Lengauer T Ceccherini-Silberstein F Perno CF Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors J Virol 2006, 80:7186-7198 1489024 16809324 10.1128/JVI.02084-05
21. Goulder PJ Phillips RE Colbert RA McAdam S Ogg G Nowak MA Giangrande P Luzzi G Morgan B Edwards A McMichael AJ Rowland-Jones S Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS Nat Med 1997, 3:212-217 10.1038/nm0297-212 9018241
22. Kagan RM Cheung PK Huard TK Lewinski MA Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment Antiviral Res 2006, 71:42-52 10.1016/j.antiviral.2006.02.008 16600392
23. Gotte M Arion D Parniak MA Wainberg MA The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis J Virol 2000, 74:3579-3585 111867 10729133 10.1128/JVI.74.8.3579-3585.2000
24. Boyer PL Sarafianos SG Arnold E Hughes SH The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1 J Virol 2002, 76:3248-3256 136050 11884549 10.1128/JVI.76.7.3248-3256.2002
25. Diallo K Gotte M Wainberg MA Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase Antimicrob Agents Chemother 2003, 47:3377-3383 253767 14576091 10.1128/ AAC.47.11.3377-3383.2003
26. Blanca G Baldanti F Paolucci S Skoblov AY Victorova L Hubscher U Gerna G Spadari S Maga G Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity J Biol Chem 2003, 278:15469-15472 10.1074/jbc.C300022200 12601008
27. Jeeninga RE Keulen W Boucher C Sanders RW Berkhout B Evolution of AZT resistance in HIV-1: The 41-70 intermediate that is not observed in vivo has a replication defect Virology 2001, 283:294-305 10.1006/ viro.2001.0888 11336554
28. Dykes C Fox K Lloyd A Chiulli M Morse E Demeter LM Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants Virology 2001, 285:193-203 10.1006/viro.2001.0920 11437654
29. Kleim JP Rosner M Winkler I Paessens A Kirsch R Hsiou Y Arnold E Riess G Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants Proc Natl Acad Sci U S A 1996, 93:34-38 40173 8552634 10.1073/pnas.93.1.34
30. Boyer PL Gao HQ Hughes SH A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer Antimicrob Agents Chemother 1998, 42:447-452 105433 9527805
31. Olivares I Sanchez-Merino V Martinez MA Domingo E Lopez-Galindez C Menendez-Arias L Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity J Virol 1999, 73:6293-6298 112707 10400720
32. Pelemans H Esnouf R Min KL Parniak M De Clercq E Balzarini J Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RT Virology 2001, 287:143-150 10.1006/ viro.2001.1032 11504549
33. Montes B Segondy M Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors J Med Virol 2002, 66:299-303 10.1002/jmv.2145 11793380
34. Girouard M Diallo K Marchand B McCormick S Gotte M Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC J Biol Chem 2003, 278:34403-34410 10.1074/jbc.M303528200 12819190
35. Hertogs K Bloor S De V V van Den EC Dehertogh P van Cauwenberge A Sturmer M Alcorn T Wegner S van Houtte M Miller V Larder BA A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V Antimicrob Agents Chemother 2000, 44:568-573 89727 10681319 10.1128/AAC.44.3.568-573.2000
36. Mason RD Bowmer MI Howley CM Gallant M Myers JC Grant MD Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes J Immunol 2004, 172:7212-7219 15153547
37. Samri A Haas G Duntze J Bouley JM Calvez V Katlama C Autran B Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells J Virol 2000, 74:9306-9312 102130 10982378 10.1128/ JVI.74.19.9306-9312.2000
38. Kesmir C Nussbaum AK Schild H Detours V Brunak S Prediction of proteasome cleavage motifs by neural networks Protein Eng 2002, 15:287-296 10.1093/protein/15.4.287 11983929
39. Nielsen M Lundegaard C Lund O Kesmir C The role of the proteasome in generating cytotoxic T-cell epitopes: Insights obtained from improved predictions of proteasomal cleavage Immunogenetics 2005, 57:33-41 10.1007/s00251-005-0781-7 15744535
40. Huang H Chopra R Verdine GL Harrison SC Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance Science 1998, 282:1669-1675 10.1126/ science.282.5394.1669 9831551
41. Chamberlain PP Ren J Nichols CE Douglas L Lennerstrand J Larder BA Stuart DI Stammers DK Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215 J Virol 2002, 76:10015-10019 136500 12208978 10.1128/JVI.76.19.10015-10019.2002
42. Nijhuis M Schuurman R de Jong D van Leeuwen R Lange J Danner S Keulen W de Groot T Boucher CA Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo J Infect Dis 1997, 176:398-405 9237704
43. Boom R Sol CJ Salimans MM Jansen CL Wertheim-van Dillen PM van der NJ Rapid and simple method for purification of nucleic acids J Clin Microbiol 1990, 28:495-503 269651 1691208
44. van Maarseveen NM Huigen MC de Jong D Smits AM Boucher CA Nijhuis M A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants J Virol Methods 2006, 133:185-194 10.1016/j.jviromet.2005.11.008 16368153
45. Boucher CA Keulen W van Bommel T Nijhuis M de Jong D de Jong MD Schipper P Back NK Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay Antimicrob Agents Chemother 1996, 40:2404-2409 163542 8891152
46. Reed LJ Muench H A simple method of estimating fifty percent endpoints Am J Hyg 1938, 27:493-497